Randomized Phase 3 Trial of Ruxolitinib for COVID-19–Associated Acute Respiratory Distress Syndrome*

Evaluate the safety and efficacy of the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib in COVID-19–associated acute respiratory distress syndrome requiring mechanical ventilation. DESIGN: Phase 3 randomized, double-blind, placebo-controlled trial Ruxolitinib in Participants With COVID-19–Associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Rein, Lindsay, Calero, Karel, Shah, Ronak, Ojielo, Charles, Hudock, Kristin M., Lodhi, Saba, Sadaka, Farid, Bellam, Shashi, Palma, Christopher, Hager, David N., Daniel, Jeannie, Schaub, Richard, O’Hayer, Kevin, Theodoropoulos, Nicole M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668361/
https://www.ncbi.nlm.nih.gov/pubmed/36226977
http://dx.doi.org/10.1097/CCM.0000000000005682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668361/
https://www.ncbi.nlm.nih.gov/pubmed/36226977
http://dx.doi.org/10.1097/CCM.0000000000005682

Ejemplares similares